Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B (rhFVIIa)

This study has been completed.
Information provided by (Responsible Party):
rEVO Biologics Identifier:
First received: October 15, 2012
Last updated: July 29, 2013
Last verified: July 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2013
  Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)